In a report released today, Stephanie Davis from Barclays reiterated a Buy rating on GoodRx Holdings (GDRX – Research Report), with a price target of $9.00. The company’s shares closed yesterday at $7.79.
According to TipRanks, Davis is an analyst with an average return of -6.7% and a 42.86% success rate. Davis covers the Healthcare sector, focusing on stocks such as Healthequity, Computer Programs and Systems, and Laboratory.
In addition to Barclays, GoodRx Holdings also received a Buy from TD Cowen’s Charles Rhyee in a report issued yesterday. However, on the same day, Goldman Sachs reiterated a Hold rating on GoodRx Holdings (NASDAQ: GDRX).
See the top stocks recommended by analysts >>
GDRX market cap is currently $2.63B and has a P/E ratio of -332.91.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GDRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GoodRx Holdings (GDRX) Company Description:
GoodRx Holdings Inc provides digital healthcare platform that provides prescription drugs at affordable prices. The company offers services like diabetes testing, general visits, blood tests, HIV testing, Vitamin D screening, Pregnancy testing, and many more.
Read More on GDRX:
- GoodRx initiated with an Outperform at Leerink
- GoodRx Holdings Enhances Financial Stability and Restructures Leadership
- J&J lawsuit may spur adoption of GoodRx program, says Citi
- GoodRx price target raised to $6.50 from $6 at Goldman Sachs
- GoodRx to eliminate role currently held by Chief Operating Officer Raj Beri
